Sofinnova Investments, Inc. holds a focused book of 61 stocks worth $2.0B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened AstraZeneca PLC and trimmed Jazz Pharmaceuticals PLC. Their largest long position is Natera Inc at 16% of the equity book. They also disclosed $595.0M in put options (a bearish bet) and $40.2M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1631134/holdings"
Use Arkolith to show Sofinnova Investments, Inc.'s latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Natera Inc COM | $310.0M | 1.55M | 15.5% | —Held | |
| 2 | Bristol-Myers Squibb Co COM | $120.6M | 1.99M | 6.0% | ▲+31% Added · +476K sh | |
| 3 | Jazz Pharmaceuticals PLC SHS USD | $113.1M | 598.3K | 5.7% | ▼−38% Reduced · −362K sh | |
| 4 | Vera Therapeutics Inc CL A | $112.4M | 2.79M | 5.6% | —Held | |
| 5 | United Therapeutics Corp COM | $94.9M | 160.1K | 4.8% | ▲+1.5% Added · +2K sh | |
| 6 | AstraZeneca PLC ORD | $89.9M | 456.0K | 4.5% | ▲New New position | |
| 7 | Cogent Biosciences Inc COM | $81.4M | 2.11M | 4.1% | ▲+7.1% Added · +140K sh | |
| 8 | Ultragenyx Pharmaceutical Inc COM | $65.9M | 3.15M | 3.3% | ▲38× Added · +3.1M sh | |
| 9 | Rapport Therapeutics Inc COM | $59.6M | 1.90M | 3.0% | —Held | |
| 10 | Insmed Inc COM PAR $.01 | $56.6M | 346.1K | 2.8% | ▲+121% Added · +189K sh | |
| 11 | Alcon AG ORD SHS | $55.0M | 730.0K | 2.8% | ▲+120% Added · +397K sh | |
| 12 | Supernus Pharmaceuticals COM | $49.3M | 954.3K | 2.5% | ▲+73% Added · +401K sh | |
| 13 | BioMarin Pharmaceutical Inc COM | $44.2M | 782.0K | 2.2% | ▲+12% Added · +85K sh | |
| 14 | Biogen Inc COM | $42.1M | 229.5K | 2.1% | ▲New New position | |
| 15 | Celcuity Inc COM | $41.8M | 366.2K | 2.1% | ▲+22% Added · +67K sh | |
| 16 | BioAge Labs Inc COM | $40.1M | 2.29M | 2.0% | —Held | |
| 17 | Rhythm Pharmaceuticals Inc COM | $39.1M | 450.1K | 2.0% | ▲+66% Added · +179K sh | |
| 18 | Arrivent BioPharma Inc COM | $39.1M | 1.70M | 2.0% | —Held | |
| 19 | IDEAYA Biosciences Inc COM | $37.7M | 1.13M | 1.9% | ▲+28% Added · +247K sh | |
| 20 | Immunome Inc COM | $37.2M | 1.70M | 1.9% | ▲+5.2% Added · +83K sh | |
| 21 | Nektar Therapeutics COM | $36.7M | 509.5K | 1.8% | ▲+16% Added · +71K sh | |
| 22 | Axsome Therapeutics Inc. COM | $36.0M | 212.7K | 1.8% | ▲17× Added · +200K sh | |
| 23 | Immatics N.V SHS | $35.7M | 3.63M | 1.8% | ▲+5.7% Added · +195K sh | |
| 24 | BridgeBio Pharma Inc COM | $30.4M | 409.2K | 1.5% | ▼−43% Reduced · −311K sh | |
| 25 | Dyne Therapeutics Inc COM | $29.6M | 1.63M | 1.5% | ▼−28% Reduced · −620K sh | |
| 26 | Inhibrx Biosciences Inc COM | $27.3M | 406.0K | 1.4% | ▼−11% Reduced · −49K sh | |
| 27 | Dexcom Inc COM | $24.7M | 393.6K | 1.2% | ▲+4.1% Added · +15K sh | |
| 28 | Pharvaris N V COM | $23.1M | 818.3K | 1.2% | ▲+9.8% Added · +73K sh | |
| 29 | Praxis Precision Medicines Inc COM | $20.5M | 63.7K | 1.0% | ▼−49% Reduced · −62K sh | |
| 30 | Genmab A/S SPONSORED ADS | $20.2M | 752.3K | 1.0% | ▲New New position | |
| 31 | Arcus Biosciences Inc COM | $19.9M | 923.1K | 1.0% | ▼−16% Reduced · −174K sh | |
| 32 | Xenon Pharmaceuticals Inc COM | $17.7M | 305.2K | 0.9% | ▲+410% Added · +245K sh | |
| 33 | Stryker Corporation COM | $14.6M | 44.5K | 0.7% | ▲New New position | |
| 34 | AnaptysBio Inc COM | $13.8M | 248.3K | 0.7% | ▼−14% Reduced · −39K sh | |
| 35 | Roivant Sciences Ltd SHS | $13.2M | 478.0K | 0.7% | ▼−35% Reduced · −257K sh | |
| 36 | Edgewise Therapeutics Inc COM | $12.2M | 386.5K | 0.6% | ▼−12% Reduced · −51K sh | |
| 37 | Compass Therapeutics Inc COM | $10.9M | 2.06M | 0.5% | ▼−39% Reduced · −1.3M sh | |
| 38 | Oric Pharmaceuticals Inc COM | $8.6M | 679.6K | 0.4% | ▲New New position | |
| 39 | Tango Therapeutics Inc COM | $8.3M | 395.1K | 0.4% | ▲New New position | |
| 40 | Tyra Biosciences Inc COM | $7.8M | 204.0K | 0.4% | ▲New New position | |
| 41 | AxoGen Inc COM | $7.0M | 210.7K | 0.3% | ▲New New position | |
| 42 | Definium Therapeutics Inc COM SHS | $6.5M | 344.2K | 0.3% | ▲New New position | |
| 43 | Cytokinetics Inc COM | $6.0M | 91.8K | 0.3% | ▲New New position | |
| 44 | Disc Medicine Inc COM | $5.0M | 78.3K | 0.3% | ▼−29% Reduced · −33K sh | |
| 45 | Veradermics Inc COMMON STOCK | $4.6M | 73.3K | 0.2% | ▲New New position | |
| 46 | Harmony Biosciences Hldgs Inc COM | $4.3M | 152.7K | 0.2% | ▲New New position | |
| 47 | Vaxcyte Inc COM | $2.9M | 50.6K | 0.1% | ▲New New position | |
| 48 | Mirum Pharmaceuticals Inc COM | $2.5M | 27.6K | 0.1% | ▲+19% Added · +4K sh | |
| 49 | Nextcure Inc COM | $2.4M | 222.7K | 0.1% | —Held | |
| 50 | Savara Inc COM | $2.0M | 364.8K | 0.1% | ▲+20% Added · +60K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | ISHARES RUSSELL 2000 ETFIWM | $148.8M | 600K |
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $134.1M | 1.1M |
| PUT · bearish | INVESCO QQQ TRUST SERIES 1QQQ | $86.6M | 150K |
| PUT · bearish | ISHARES BIOTECHNOLOGY ETFIBB | $80.2M | 475K |
| PUT · bearish | UNITED THERAPEUTICS CORPUTHR | $47.6M | 80K |
| PUT · bearish | CELCUITY INCCELC | $34.2M | 300K |
| PUT · bearish | AXSOME THERAPEUTICS INCAXSM | $33.8M | 200K |
| CALL · bullish | PFIZER INCPFE | $22.5M | 800K |
| PUT · bearish | LIQUIDIA CORPLQDA | $18.9M | 500K |
| PUT · bearish | EXELIXIS INCEXEL | $10.8M | 252K |
| CALL · bullish | REPLIMUNE GROUP INCREPL | $7.8M | 1.0M |
| CALL · bullish | ULTRAGENYX PHARMACEUTICAL INRARE | $7.3M | 350K |
| CALL · bullish | COMPASS THERAPEUTICS INCCMPX | $2.6M | 500K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 75 | $2.6B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 60 | $2.3B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 62 | $1.8B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 63 | $1.6B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 65 | $1.5B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 61 | $1.4B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 62 | $1.3B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 9, 2024 | 82 | $1.9B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | Aug 14, 2024 | 74 | $1.8B | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Aug 15, 2024 | 64 | $1.8B | 13F-HR/A |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 69 | $1.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 55 | $1.5B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 | 53 | $1.6B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 53 | $1.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 8, 2022 | 61 | $1.7B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 61 | $1.2B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 64 | $1.3B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 72 | $1.7B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 70 | $1.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 67 | $1.7B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 64 | $1.7B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 69 | $1.7B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.